Tennessee Senate Bill SB0401

Tennessee 2023-2024 Regular Session

• Introduced: 1/24/23
• Engrossed: 2/13/23
• Enrolled: 4/3/23
• Passed: 4/17/23
• Chaptered: 4/25/23

Caption

AN ACT to amend Tennessee Code Annotated, Title 56, Chapter 7, Part 23, relative to the Proton Therapy Access Act.

Impact

The implementation of SB0401 is expected to positively impact state laws surrounding healthcare access, particularly for cancer treatment options. By mandating that insurance providers cover hypofractionated proton therapy under specified guidelines, this legislation aims to reduce financial barriers for patients and encourage the utilization of advanced treatment methods. Proponents argue that this measure will ensure that patients have access to cutting-edge therapies and that reimbursement processes will be fair and transparent. The required alignment with existing standard treatment protocols could also enhance the medical community's acceptance of proton therapy as a viable treatment method.

Summary

Senate Bill 0401, also known as the Proton Therapy Access Act, aims to amend Tennessee Code Annotated by facilitating access to hypofractionated proton therapy for cancer patients under the state group insurance program. The bill specifies that reimbursement for this advanced radiation therapy should align with the costs covered for standard radiation treatments, specifically IMRT (Intensity Modulated Radiation Therapy), provided certain conditions are met. These conditions include patient eligibility, board certification of the prescribing radiation oncologist, and the treatment facility being located within Tennessee. The bill seeks to standardize care and enhance access to modern treatment options for eligible patients, ultimately aiming to improve cancer care outcomes in the state.

Sentiment

The sentiment surrounding SB0401 appears largely favorable, with support from medical professionals advocating for greater access to innovative cancer treatments. Supporters praise the bill for recognizing the necessity of diverse therapy options, arguing that it reflects an important evolution in cancer care. However, skepticism exists among some healthcare policymakers concerning the cost implications for the state insurance program and whether this could strain resources. Overall, there remains a strong belief in the bill’s potential to enhance patient care.

Contention

Notable points of contention regarding SB0401 revolve around the financial feasibility of expanding coverage for proton therapy. While advocates emphasize the therapeutic benefits and long-term health outcomes associated with hypofractionated proton therapy, critics express concerns about the increased costs to the state’s insurance program and the broader implications for healthcare funding. There are discussions related to whether this legislation might lead to disparities in treatment access based on insurance provider capabilities and whether all cancer patients will see equal benefits from such state mandates.